Nutritional impact of antipseudomonas intravenous antibiotic courses in cystic fibrosis

Arch Dis Child. 1997 May;76(5):437-40. doi: 10.1136/adc.76.5.437.

Abstract

Objective: To evaluate the short term effects on nutritional status of home intravenous anti-pseudomonas antibiotic courses in cystic fibrosis (CF) patients chronically colonised with Pseudomonas aeruginosa.

Design: A prospective study involving 38 CF patients, mean age 10.9 (SD 4.3) years (range 4.3 to 22.2 years), presenting with pulmonary exacerbations of P aeruginosa infection. The patients received a 14 day antibiotic course of intravenous ceftazidime (200 mg/kg/day) and either amikacin (35 mg/kg/day) or tobramycin (15 mg/kg/day). Nutritional evaluation on days 1 and 14 involved measurements of weight, weight/height ratio (per cent of predicted value), energy intake (per cent of recommended daily allowances), serum prealbumin, and body composition assessed by two methods: bioelectrical analysis (BIA) and skinfold anthropometry. The non-parametric Wilcoxon t test was used for statistical analysis, with a Bland-Altman plot to assess the degree of agreement between the two methods of evaluating body composition.

Results: Weight increased by 1.0 (0.8) kg (p < 0.001); weight/height increased from 94.4(12.2)% to 98(12.7)% (p < 0.001), energy intake from 107(32)% to 119(41)% (p < 0.02), and prealbumin from 183 (63) to 276 (89) mg/l (p < 0.001). Fat mass increased by 0.8 (1.0) kg (p < 0.001), without any significant change in fat-free mass. The limits of agreement between BIA and anthropometry were -0.7 kg and +1.1 kg.

Conclusions: Antibiotic courses allow an improvement in nutritional status in CF patients, with a gain in fat mass.

Publication types

  • Clinical Trial
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adolescent
  • Adult
  • Amikacin / therapeutic use
  • Anthropometry
  • Body Composition
  • Ceftazidime / therapeutic use
  • Child
  • Child, Preschool
  • Chronic Disease
  • Cystic Fibrosis / complications*
  • Drug Therapy, Combination / therapeutic use*
  • Female
  • Humans
  • Male
  • Nutritional Status*
  • Opportunistic Infections / complications
  • Opportunistic Infections / drug therapy*
  • Prospective Studies
  • Pseudomonas Infections / complications
  • Pseudomonas Infections / drug therapy*
  • Tobramycin / therapeutic use

Substances

  • Amikacin
  • Ceftazidime
  • Tobramycin